Triple-drug attack shows promise against tough liver cancer
NCT ID NCT05166239
First seen Feb 01, 2026 · Last updated May 16, 2026 · Updated 17 times
Summary
This study tested a three-drug combination for people with advanced liver cancer that has spread into the portal vein. The treatment adds a direct liver chemo infusion to two standard drugs (lenvatinib and a PD-1 inhibitor). 66 patients took part to see if the triple therapy works better than the two-drug approach alone. The goal was to control the cancer and improve survival, not to cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Univerisity Cancer Hospital
Beijing, Beijing Municipality, 100142, China
Conditions
Explore the condition pages connected to this study.